A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Study Summary

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Conditions

Chondral Defect Osteochondritis Dissecans (OCD)Articular Cartilage Defect Articular Cartilage Disorder of Knee

Interventions / Drugs

MACI microfracture

View on ClinicalTrials.gov ↗

Sponsor

VCEL

Vericel Corporation

Regenerative Medicine

D37/100

Study Details

Enrollment45 participants

Primary Completion—

Lead SponsorVericel Corporation

Data Retrieved2026-04-11 04:30:51.495467+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.